169 related articles for article (PubMed ID: 23852799)
21. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Murugan AK; Hong NT; Fukui Y; Munirajan AK; Tsuchida N
Int J Oncol; 2008 Jan; 32(1):101-11. PubMed ID: 18097548
[TBL] [Abstract][Full Text] [Related]
22. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
[TBL] [Abstract][Full Text] [Related]
23. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma.
Pedrero JM; Carracedo DG; Pinto CM; Zapatero AH; Rodrigo JP; Nieto CS; Gonzalez MV
Int J Cancer; 2005 Mar; 114(2):242-8. PubMed ID: 15543611
[TBL] [Abstract][Full Text] [Related]
24. A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth.
Ruicci KM; Meens J; Sun RX; Rizzo G; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Boutros PC; Ailles L; Nichols AC
Int J Cancer; 2019 Oct; 145(8):2100-2106. PubMed ID: 30468243
[TBL] [Abstract][Full Text] [Related]
25. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
Hafner C; Landthaler M; Vogt T
Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
[TBL] [Abstract][Full Text] [Related]
26. Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.
Cohen Y; Goldenberg-Cohen N; Shalmon B; Shani T; Oren S; Amariglio N; Dratviman-Storobinsky O; Shnaiderman-Shapiro A; Yahalom R; Kaplan I; Hirshberg A
Oral Oncol; 2011 Oct; 47(10):946-50. PubMed ID: 21824802
[TBL] [Abstract][Full Text] [Related]
27. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.
Young NR; Liu J; Pierce C; Wei TF; Grushko T; Olopade OI; Liu W; Shen C; Seiwert TY; Cohen EE
Mol Oncol; 2013 Jun; 7(3):359-68. PubMed ID: 23200321
[TBL] [Abstract][Full Text] [Related]
28. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review.
Perisanidis C
In Vivo; 2017 Jan; 31(1):23-34. PubMed ID: 28064216
[TBL] [Abstract][Full Text] [Related]
30. Novel insight into mutational landscape of head and neck squamous cell carcinoma.
Gaykalova DA; Mambo E; Choudhary A; Houghton J; Buddavarapu K; Sanford T; Darden W; Adai A; Hadd A; Latham G; Danilova LV; Bishop J; Li RJ; Westra WH; Hennessey P; Koch WM; Ochs MF; Califano JA; Sun W
PLoS One; 2014; 9(3):e93102. PubMed ID: 24667986
[TBL] [Abstract][Full Text] [Related]
31. A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3.
Sakane T; Murase T; Okuda K; Saida K; Masaki A; Yamada T; Saito Y; Nakanishi R; Inagaki H
Histopathology; 2019 Nov; 75(5):755-766. PubMed ID: 31179560
[TBL] [Abstract][Full Text] [Related]
32. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
Rekhtman N; Paik PK; Arcila ME; Tafe LJ; Oxnard GR; Moreira AL; Travis WD; Zakowski MF; Kris MG; Ladanyi M
Clin Cancer Res; 2012 Feb; 18(4):1167-76. PubMed ID: 22228640
[TBL] [Abstract][Full Text] [Related]
33. Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for
Hedberg ML; Peyser ND; Bauman JE; Gooding WE; Li H; Bhola NE; Zhu TR; Zeng Y; Brand TM; Kim MO; Jordan RCK; VandenBerg S; Olivas V; Bivona TG; Chiosea SI; Wang L; Mills GB; Johnson JT; Duvvuri U; Ferris RL; Ha P; Johnson DE; Grandis JR
J Exp Med; 2019 Feb; 216(2):419-427. PubMed ID: 30683736
[No Abstract] [Full Text] [Related]
34. High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer.
Nichols AC; Palma DA; Chow W; Tan S; Rajakumar C; Rizzo G; Fung K; Kwan K; Wehrli B; Winquist E; Koropatnick J; Mymryk JS; Yoo J; Barrett JW
JAMA Otolaryngol Head Neck Surg; 2013 Jun; 139(6):617-22. PubMed ID: 23787421
[TBL] [Abstract][Full Text] [Related]
35. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
García-Escudero R; Segrelles C; Dueñas M; Pombo M; Ballestín C; Alonso-Riaño M; Nenclares P; Álvarez-Rodríguez R; Sánchez-Aniceto G; Ruíz-Alonso A; López-Cedrún JL; Paramio JM; Lorz C
Oral Oncol; 2018 Apr; 79():55-63. PubMed ID: 29598951
[TBL] [Abstract][Full Text] [Related]
37. Molecular profiling of head and neck squamous cell carcinoma.
Feldman R; Gatalica Z; Knezetic J; Reddy S; Nathan CA; Javadi N; Teknos T
Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E1625-38. PubMed ID: 26614708
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
39. Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation.
Tinhofer I; Stenzinger A; Eder T; Konschak R; Niehr F; Endris V; Distel L; Hautmann MG; Mandic R; Stromberger C; Weichert W; Budach V
Ann Oncol; 2016 Dec; 27(12):2262-2268. PubMed ID: 27681865
[TBL] [Abstract][Full Text] [Related]
40. AKT3 is a key regulator of head and neck squamous cell carcinoma.
Takahashi H; Rokudai S; Kawabata-Iwakawa R; Sakakura K; Oyama T; Nishiyama M; Chikamatsu K
Cancer Sci; 2021 Jun; 112(6):2325-2334. PubMed ID: 33811778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]